Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis
A phase 3 trial of Florastamin F-18 run by FutureChem, active.
Overview
Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis is a phase 3 interventional study registered as NCT05004285 by FutureChem, with 398 participants planned, started 2021-04-28. Conditions listed: High Risk Prostate Carcinoma. No results are recorded here; the registry entry is the source.
Setting
A Multi Center, Non-randomized, Open, Phase 3 Study to Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis in Prostate Cancer Risk Groups
Phase
Phase 3
Sponsor
FutureChem
Registry
Enrolled
398